Literature DB >> 2013116

Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas.

M Jäckel1, P Köpf-Maier.   

Abstract

The scope of the present study was to examine whether the cytokinetic phenomena occurring in human tumors under the influence of cisplatin correlate with the response of the tumors to therapy with the drug. Therefore, three strains of heterotransplanted human head and neck carcinomas showing different degrees of sensitivity to cisplatin were investigated by flow cytometry at various intervals after a single administration of cisplatin at four different dose levels (3, 6, 9 or 12 mg/kg). Three types of cell-cycle alterations were observed that depended on the dose of cisplatin and the degree of drug sensitivity shown by the tumors investigated. The obviously weakest kind of tumor reaction was a delay in the G2 cell phase. This phenomenon also occurred in the case of non-responsiveness to therapy, whereby the growth, histological structure and mitotic activity of the tumors remained nearly unaltered after cisplatin treatment. With increasing cytotoxicity, additional accumulations of cells in the S phase and, finally, long-lasting blocks at the G1/S boundary were found. The latter phenomenon, which manifested at high dose levels used in sensitive tumors, was obviously irreversible, as it did not completely disappear until the tumor cells had died and been removed by immigrating macrophages. It was always accompanied by severe histological destruction, tumor cell necrotization, and marked depression of the mitotic index. Thus, the hindrance of cell traversal through the S phase obviously represents the main and significant cytokinetic event, which indicates a potent antitumor effect for cisplatin that leads to pronounced tumor regression. This finding supports the hypothesis that inhibition of DNA synthesis is the mechanism underlying the cytotoxicity of cisplatin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013116     DOI: 10.1007/bf00685161

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Interactions between mammalian cell DNA and inorganic platinum compounds. II. Interstrand cross-linking of isolated and cellular DNA by platinum(IV) compounds.

Authors:  J M Pascoe; J J Roberts
Journal:  Biochem Pharmacol       Date:  1974-05-01       Impact factor: 5.858

Review 2.  The molecular basis of drug-induced G2 arrest in mammalian cells.

Authors:  P N Rao
Journal:  Mol Cell Biochem       Date:  1980-01-16       Impact factor: 3.396

Review 3.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

Authors:  A L Pinto; S J Lippard
Journal:  Biochim Biophys Acta       Date:  1985

Review 4.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

5.  In vitro cytokinetic response of human colon cancer cells to cis-dichlorodiammineplatinum(II).

Authors:  J P Bergerat; B Barlogie; W Göhde; D A Johnston; B Drewinko
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

Review 6.  Cisplatin: synthesis, antitumour activity and mechanism of action.

Authors:  J Reedijk; P H Lohman
Journal:  Pharm Weekbl Sci       Date:  1985-10-25

7.  Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro.

Authors:  P Köpf-Maier; W Wagner; E Liss
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

8.  24-hour infusion of cis-platinum in head and neck cancers.

Authors:  C Jacobs; J R Bertino; D R Goffinet; W E Fee; R L Goode
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

9.  Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy.

Authors:  V L Randolph; A Vallejo; R H Spiro; J Shah; E W Strong; A G Huvos; R E Wittes
Journal:  Cancer       Date:  1978-02       Impact factor: 6.860

10.  Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.

Authors:  B J Braakhuis; E J Schoevers; E C Heinerman; G Sneeuwloper; G B Snow
Journal:  Br J Cancer       Date:  1983-11       Impact factor: 7.640

View more
  8 in total

1.  Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line.

Authors:  G Chen; K J Hutter; J Bullerdiek; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin.

Authors:  M C Jäckel; R Tausch-Treml; P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells.

Authors:  Itaru Sato; Masanari Umemura; Kenji Mitsudo; Mitomu Kioi; Hideyuki Nakashima; Toshinori Iwai; Xianfeng Feng; Kayoko Oda; Akiyoshi Miyajima; Ayako Makino; Maki Iwai; Takayuki Fujita; Utako Yokoyama; Satoshi Okumura; Motohiko Sato; Haruki Eguchi; Iwai Tohnai; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2014-03-12       Impact factor: 2.781

5.  The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Authors:  Eva Roubalová; Veronika Kvardová; Roman Hrstka; Sárka Borilová; Eva Michalová; Lenka Dubská; Petr Müller; Petr Sova; Borivoj Vojtesek
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

6.  Lack of cell-cycle-specific effects of recombinant tumor necrosis factor in vivo.

Authors:  M Jäckel; P Köpf-Maier; R Tausch-Treml
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

7.  Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo.

Authors:  Nanae Yatagai; Takumi Hasegawa; Rika Amano; Izumi Saito; Satomi Arimoto; Daisuke Takeda; Yasumasa Kakei; Masaya Akashi
Journal:  Biomed Res Int       Date:  2021-07-02       Impact factor: 3.411

8.  Rad5 template switch pathway of DNA damage tolerance determines synergism between cisplatin and NSC109268 in Saccharomyces cerevisiae.

Authors:  Dilip Jain; Wolfram Siede
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.